Development code · Small Molecule
KarXT
KarXT is a development code for Xanomeline/trospium chloride (Cobenfy), developed by Karuna Therapeutics.
- Status
- Approved for Schizophrenia
- Mechanism
- M4 Agonist
- Developer
- Karuna Therapeutics
Programs
- Xanomeline/trospium chloride (Cobenfy) for SchizophreniaApprovedApproved
- Xanomeline/trospium chloride (Cobenfy) for Alzheimer's disease psychosisPhase 3Recruiting
Also known as
- Cobenfy
- xanomeline-trospium
- xanomeline and trospium chloride
- xanomeline
- LY-246708
- 131986-45-3
- trospium chloride
- 10405-02-4
- KarX-EC
View the full Xanomeline/trospium chloride (Cobenfy) profile →